Literature DB >> 20354543

Chemotherapy: Current drugs still have potential in advanced ovarian cancer.

Thomas Hogberg1.   

Abstract

Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20354543     DOI： 10.1038/nrclinonc.2010.37

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

Authors:  Andreas du Bois; Beatrice Weber; Justine Rochon; Werner Meier; Alain Goupil; Sigrid Olbricht; Jean-Claude Barats; Walther Kuhn; Hubert Orfeuvre; Uwe Wagner; Barbara Richter; Hans-Joachim Lueck; Jacobus Pfisterer; Serban Costa; Willibald Schroeder; Rainer Kimmig; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

3.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

4.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

Authors:  A du Bois; M Quinn; T Thigpen; J Vermorken; E Avall-Lundqvist; M Bookman; D Bowtell; M Brady; A Casado; A Cervantes; E Eisenhauer; M Friedlaender; K Fujiwara; S Grenman; J P Guastalla; P Harper; T Hogberg; S Kaye; H Kitchener; G Kristensen; R Mannel; W Meier; B Miller; J P Neijt; A Oza; R Ozols; M Parmar; S Pecorelli; J Pfisterer; A Poveda; D Provencher; E Pujade-Lauraine; M Randall; J Rochon; G Rustin; S Sagae; F Stehman; G Stuart; E Trimble; P Vasey; I Vergote; R Verheijen; U Wagner
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

5.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Fumiaki Takahashi; Seiji Isonishi; Toshiko Jobo; Daisuke Aoki; Hiroshi Tsuda; Toru Sugiyama; Shoji Kodama; Eizo Kimura; Kazunori Ochiai; Kiichiro Noda
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

6.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
  7 in total
  5 in total

1.  Weekly paclitaxel in ovarian cancer-the latest success story.

Authors:  A Jain; B Dubashi; K S Reddy; P Jain
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

2.  Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.

Authors:  Deolinda Pereira; Joana Assis; Mónica Gomes; Augusto Nogueira; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2016-01-23       Impact factor: 2.953

3.  Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.

Authors:  Junnai Wang; Qinglei Gao; Qiang Li
Journal:  Tumour Biol       Date:  2015-03-29

4.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Authors:  Alexandria M Haslehurst; Madhuri Koti; Moyez Dharsee; Paulo Nuin; Ken Evans; Joseph Geraci; Timothy Childs; Jian Chen; Jieran Li; Johanne Weberpals; Scott Davey; Jeremy Squire; Paul C Park; Harriet Feilotter
Journal:  BMC Cancer       Date:  2012-03-19       Impact factor: 4.430

5.  IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer.

Authors:  Samina Dongol; Qing Zhang; Chunping Qiu; Chenggong Sun; Zhiwei Zhang; Huan Wu; Beihua Kong
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.